EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Emerging Therapeutics for Primary Biliary Cholangitis

Eun Ju Cho iD

The Korean Journal of Gastroenterology · 2025

DOI: 10.4166/kjg.2025.045 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Korean Journal of Gastroenterology, 2025. Verfasst von Eun Ju Cho. Beteiligte Einrichtung: Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Liver Cirrhosis, Biliary. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Primary biliary cholangitis (PBC) is an autoimmune liver disease characterized by progressive destruction of the intrahepatic bile ducts, potentially leading to cirrhosis and end-stage liver disease. Ursodeoxycholic acid (UDCA) has been the standard first-line therapy, but up to one-third of patients show an unsatisfactory response to UDCA, underscoring the need for novel treatments. Obeticholic acid is an approved second-line treatment targeting the farnesoid X receptor, but it is associated with adverse effects such as pruritus and the potential risk of hepatic decompensation in patients with advanced disease. Recently, selective peroxisome proliferator-activated receptor (PPAR) agonists, including seladelpar (a PPAR-δ agonist) and elafibranor (dual PPAR-α/δ agonist), have shown substantial efficacy and favorable safety profiles in phase three clinical trials. In addition, emerging therapeutics for symptom relief, such as NOX inhibitors and ileal bile acid transporter inhibitors, further expand the treatment options. These advances offer new opportunities for the improved management of patients with PBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver Cirrhosis, BiliaryHumansChenodeoxycholic AcidUrsodeoxycholic AcidReceptors, Cytoplasmic and NuclearPeroxisome Proliferator-Activated ReceptorsPropionatesCholagogues and CholereticsChalconesReceptor, Farnesoid X-Activated

Stichwörter der Autor:innen

Liver cirrhosis, biliaryTreatment

Substanzen

Chenodeoxycholic AcidUrsodeoxycholic AcidReceptors, Cytoplasmic and NuclearPeroxisome Proliferator-Activated ReceptorsPropionatesCholagogues and CholereticsChalconesReceptor, Farnesoid X-Activatedobeticholic acid2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid

Autor:innen und Institutionen

  • Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.

ORCID-Profile: Eun Ju Cho

Zitieren

APA

Cho, E. J. (2025). Emerging Therapeutics for Primary Biliary Cholangitis. The Korean Journal of Gastroenterology. https://doi.org/10.4166/kjg.2025.045

Vancouver

Cho EJ. Emerging Therapeutics for Primary Biliary Cholangitis. The Korean Journal of Gastroenterology. 2025. doi:10.4166/kjg.2025.045

BibTeX
@article{Cho2025,
  author = {Cho, Eun Ju},
  title = {Emerging Therapeutics for Primary Biliary Cholangitis},
  journal = {The Korean Journal of Gastroenterology},
  year = {2025},
  doi = {10.4166/kjg.2025.045}
}
Kostenlos starten →